Citi analyst Joanne Wuensch raised the firm’s price target on Johnson & Johnson to $215 from $213 and keeps a Buy rating on the shares. The company reported solid Q3 results and announced a spin of the orthopedic business, the analyst tells investors in a research note. Citi says the spinout “adds intrigue” to the J&J story.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Johnson & Johnson price target raised to $222 from $185 at TD Cowen
- Johnson & Johnson’s Strong Q3 Performance and Strategic Initiatives Drive Buy Rating
- Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
- Midday Fly By: Big banks report beats, GM takes $1.6B EV charge
- Johnson & Johnson price target raised to $214 from $190 at UBS